CD19 Chimeric Antigen Receptor-T Cells As Bridging Therapy to Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Patients with Refractory/relapsed B-cell Acute Lymphoblastic Leukemia

Jie Liu,Mengyuan Xu,Xiaoqian Zhang,Zhuo Zhang,Tao Zhong,Hongjuan Yu,Yueyue Fu,Hongbin Meng,Jiawei Feng,Xindi Zou,Xueying Han,Liqing Kang,Lei Yu,Limin Li
DOI: https://doi.org/10.1016/j.heliyon.2024.e33937
IF: 3.776
2024-01-01
Heliyon
Abstract:Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone. In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.
What problem does this paper attempt to address?